Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) Research & Development (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Research & Development for 13 consecutive years, with $634000.0 as the latest value for Q3 2025.

  • Quarterly Research & Development fell 9.56% to $634000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Sep 2025, down 8.11% year-over-year, with the annual reading at $2.4 million for FY2024, 78.52% up from the prior year.
  • Research & Development for Q3 2025 was $634000.0 at Xtant Medical Holdings, up from $566000.0 in the prior quarter.
  • The five-year high for Research & Development was $701000.0 in Q3 2024, with the low at $151000.0 in Q4 2021.
  • Average Research & Development over 5 years is $376315.8, with a median of $262000.0 recorded in 2021.
  • The sharpest move saw Research & Development dropped 25.31% in 2023, then skyrocketed 253.33% in 2024.
  • Over 5 years, Research & Development stood at $151000.0 in 2021, then soared by 53.64% to $232000.0 in 2022, then skyrocketed by 112.07% to $492000.0 in 2023, then rose by 6.1% to $522000.0 in 2024, then rose by 21.46% to $634000.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $634000.0, $566000.0, and $443000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.